<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02085863</url>
  </required_header>
  <id_info>
    <org_study_id>TV5600-PK-10017</org_study_id>
    <secondary_id>2013-005356-14</secondary_id>
    <nct_id>NCT02085863</nct_id>
  </id_info>
  <brief_title>A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Two-way Crossover Drug-drug Interaction Study to Assess the Effect of Laquinimod 0.6 mg on the Pharmacokinetics and Pharmacodynamics of Ethinylestradiol and Levonorgestrel in Healthy Young Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, double blind, placebo controlled, 2-way crossover&#xD;
      drug-drug interaction (DDI) study to assess the effect of laquinimod on the PK and PD of&#xD;
      ethinylestradiol (EE) and levonorgestrel (LNG) a commonly used oral contraceptive&#xD;
      combination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-24 of EE and LNG plasma concentrations.</measure>
    <time_frame>10 min prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose</time_frame>
    <description>to assess the effect of once daily oral doses of laquinimod on the pharmacokinetics (PK) of ethinylestradiol (EE) and levonorgestrel (LNG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of EE and LNG plasma concentrations.</measure>
    <time_frame>10 min prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose</time_frame>
    <description>to assess the effect of once daily oral doses of laquinimod on the pharmacokinetics (PK) of ethinylestradiol (EE) and levonorgestrel (LNG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of EE and LNG plasma concentrations</measure>
    <time_frame>10 min prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of laquinimod plasma concentrations</measure>
    <time_frame>10 min prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 of progesterone</measure>
    <time_frame>10 min prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of luteinizing hormone [LH], and follicle-stimulating hormone [FSH]</measure>
    <time_frame>10 min prior to dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participants with Adverse Events</measure>
    <time_frame>25 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of EE and LNG plasma concentrations</measure>
    <time_frame>10 min prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of EE and LNG plasma concentrations</measure>
    <time_frame>10 min prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F of EE and LNG plasma concentrations</measure>
    <time_frame>10 min prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of laquinimod plasma concentrations</measure>
    <time_frame>10 min prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 of laquinimod plasma concentrations</measure>
    <time_frame>10 min prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of progesterone</measure>
    <time_frame>10 min prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Pharmacodynamics</condition>
  <arm_group>
    <arm_group_label>Laquinimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily oral doses of laquinimod (with combination oral contraceptives)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo (with combination oral contraceptives)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>laquinimod</intervention_name>
    <description>Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)</description>
    <arm_group_label>Laquinimod</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>TV5600</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)</description>
    <arm_group_label>Laquinimod</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pre-menopausal women of age 18 to 40 years, who are healthy, non-pregnant and not&#xD;
             planning pregnancy within the study period.&#xD;
&#xD;
          2. Women of childbearing potential who are willing to continuously use the oral&#xD;
             contraceptive (OC) product containing EE 30 μg and LNG 150 μg from at least the&#xD;
             commencement of their last normal period prior to the first dose of study medication&#xD;
             and for a total of 4 consecutive cycles.&#xD;
&#xD;
          3. Willing to use a double barrier method of contraception (condom or diaphragm with&#xD;
             spermicide) from screening until 30 days after the last laquinimod/placebo treatment.&#xD;
             During administration of OC, the double barrier method should also be used.&#xD;
&#xD;
          4. Body Mass Index ranging from 18-30 kg/m2, inclusive.&#xD;
&#xD;
          5. Must be in a good health as determined by medical history, electrocardiogram (ECG),&#xD;
             vital signs, physical and gynecological examination, and clinical laboratory tests.&#xD;
&#xD;
          6. Must have a regular menstrual cycle of 25 to 35 days (28-3/+7days) in the preceding 3&#xD;
             months prior to screening.&#xD;
&#xD;
          7. Subjects must be able to understand the requirements of the study and be willing to&#xD;
             comply with the requirements of the study (eg, all dietary, exercise, tobacco and&#xD;
             alcohol restrictions) and provide their written informed consent to participate in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who smoke at any frequency, have smoked in the last 6 months, or are planning&#xD;
             to start smoking during the study, tobacco users, subjects currently using nicotine&#xD;
             products (patches, gums, etc.) or subjects with a positive urine cotinine test at&#xD;
             screening and/or at day -7.&#xD;
&#xD;
          2. Subjects with a known drug hypersensitivity to laquinimod, or one of its excipients&#xD;
             (ie, mannitol, meglumine, or sodium stearyl fumarate).&#xD;
&#xD;
          3. Subjects with any significant food/drug allergies at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
          4. Subjects who are pregnant or lactating.&#xD;
&#xD;
          5. Subjects who had one of the following conditions in the noted amount of time prior to&#xD;
             screening or at any time between screening and day -7: o Major trauma or surgery in&#xD;
             the past 2 months.&#xD;
&#xD;
             -Acute infection within 2 weeks (14 days).&#xD;
&#xD;
          6. Any malignancies, excluding basal cell carcinoma, prior to randomization.&#xD;
&#xD;
          7. Subjects who have any condition that possibly interferes with drug absorption,&#xD;
             distribution, metabolism, or excretion.&#xD;
&#xD;
          8. Subjects suffering from, or with history of, one of the following: cardiovascular,&#xD;
             respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological,&#xD;
             or psychiatric disorder(s), or a history of any illness that, in the opinion of the&#xD;
             Investigator, might pose additional risk to the subject by participation in the study&#xD;
             or confound the results of the study.&#xD;
&#xD;
          9. Subjects suffering from any condition in which the OC is contra indicated or not&#xD;
             recommended.&#xD;
&#xD;
         10. Subjects who have used patches/intrauterine device/injectable hormonal contraception&#xD;
             within 6 month prior to screening.&#xD;
&#xD;
         11. History of irregular menstruation.&#xD;
&#xD;
         12. Subjects with clinically relevant abnormality (judged by the investigator) of serum&#xD;
             electrolytes or complete blood count.&#xD;
&#xD;
         13. Serum levels of ≥2× upper limit of normal alanine aminotransferase or aspartate&#xD;
             aminotransferase or gamma-glutamyltransferase or alkaline phosphatase or direct&#xD;
             bilirubin.&#xD;
&#xD;
         14. Subjects who have used one of the forbidden drugs or foods as following: o Excessive&#xD;
             amounts (defined as daily intake of alcohol &gt;40 g) of alcoholic beverages (eg, beer,&#xD;
             wine, distilled spirits), or have a history of alcohol abuse, or are unwilling to&#xD;
             comply with the restricted use of alcoholic beverages during the study.&#xD;
&#xD;
               -  An investigational drug (new chemical entity) during the 90 days or 5 half-lives&#xD;
                  prior to day -7 (whichever is longer).&#xD;
&#xD;
               -  Any medications, including over-the-counter medications or herbal preparations,&#xD;
                  used within 14 days prior to day -7 (except occasional paracetamol/acetaminophen&#xD;
                  or ibuprofen use and OC).&#xD;
&#xD;
               -  Any contraindicated concomitant medication according to the OC labeling.&#xD;
&#xD;
               -  Inducers or inhibitors of cytochrome P450 3A4 within 30 days prior to day -7.&#xD;
&#xD;
               -  Subjects who have consumed grapefruit, grapefruit juice, Seville oranges and&#xD;
                  pomelo-containing products, within the 14 days (2 weeks) prior to day -7.&#xD;
&#xD;
         15. Subjects with a positive urine drug test (cocaine, amphetamines, barbiturates,&#xD;
             opiates, benzodiazepines, tetrahydrocannabinol) or positive test for ethanol at&#xD;
             screening or at day -7.&#xD;
&#xD;
         16. Subjects who have donated or received any blood, plasma, or platelet transfusions in&#xD;
             the 3 months prior to day -7, or who have made donations on more than 2 occasions&#xD;
             within the 12 months preceding day -7, or who have planned donations during the study&#xD;
             period or during the 3 months following the study.&#xD;
&#xD;
         17. Subjects with a positive screening test for hepatitis B surface antigen, hepatitis C&#xD;
             antibody, or human immunodeficiency virus antibody at screening.&#xD;
&#xD;
         18. Subjects who cannot participate or successfully complete the study, in the opinion of&#xD;
             their general practitioner or the investigator, for the following reasons: o Subjects&#xD;
             are under the legal age of consent or are mentally or legally incapacitated, or unable&#xD;
             to give consent for any reason.&#xD;
&#xD;
               -  Subjects who are in custody due to an administrative or a legal decision, or&#xD;
                  under tutelage, or being admitted to a sanitarium or social institution.&#xD;
&#xD;
               -  Subjects unable to be contacted in case of emergency.&#xD;
&#xD;
               -  Subjects who are employed by the Sponsor or the investigational site conducting&#xD;
                  the study&#xD;
&#xD;
               -  Any other reason, at the discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Branded Pharmaceutical Products R&amp;D, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 32415</name>
      <address>
        <city>Moenchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

